Cancer waiting times: patients starting treatment and patients informed they do not have cancer, June 2019 onwards

Data values	Data description	Date	local health board	tumour site	sex	age group
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Total	40-49
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Head and neck	Male	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Gynaecological	Female	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Female	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Gynaecological	Female	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Head and neck	Total	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Head and neck	Total	40-49
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Breast	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Lower Gastrointestinal	Male	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Gynaecological	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Haematological (excluding acute leukaemia)	Male	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Male	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Lung	Female	40-49
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Gynaecological	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Head and neck	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Haematological (excluding acute leukaemia)	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Sarcoma	Female	Total
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Haematological (excluding acute leukaemia)	Female	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Lower Gastrointestinal	Male	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Breast	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	All sites	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Head and neck	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Breast	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Gynaecological	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Urological	Male	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Haematological (excluding acute leukaemia)	Male	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Total	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Male	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	All sites	Female	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Lower Gastrointestinal	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Sarcoma	Female	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Gynaecological	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Haematological (excluding acute leukaemia)	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Head and neck	Male	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Gynaecological	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Haematological (excluding acute leukaemia)	Male	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Lower Gastrointestinal	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Sarcoma	Total	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Gynaecological	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Gynaecological	Female	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Head and neck	Male	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Lower Gastrointestinal	Total	90+
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Sarcoma	Total	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Skin	Female	Under 30
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Female	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	All sites	Female	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Head and neck	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Lung	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Breast	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Gynaecological	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Gynaecological	Total	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Gynaecological	Female	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Urological	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Haematological (excluding acute leukaemia)	Total	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Haematological (excluding acute leukaemia)	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	Haematological (excluding acute leukaemia)	Male	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Head and neck	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Total	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	All sites	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	All sites	Male	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Lower Gastrointestinal	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Lower Gastrointestinal	Male	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Sarcoma	Total	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Sarcoma	Male	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Skin	Male	Under 30
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Gynaecological	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Urological	Total	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Urological	Male	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Wales	Haematological (excluding acute leukaemia)	Male	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Head and neck	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Upper Gastrointestinal	Female	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Lower Gastrointestinal	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Gynaecological	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Betsi Cadwaladr	Haematological (excluding acute leukaemia)	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Lower Gastrointestinal	Total	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Lower Gastrointestinal	Male	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Lung	Female	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Sarcoma	Total	Total
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Sarcoma	Female	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Skin	Female	90+
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Gynaecological	Total	50-59
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Hywel Dda	Gynaecological	Female	30-39
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Head and neck	Total	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Head and neck	Male	40-49
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Head and neck	Female	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Head and neck	Female	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Lower Gastrointestinal	Male	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Lower Gastrointestinal	Male	90+
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Sarcoma	Male	70-79
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Skin	Total	Under 30
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Total	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Total	80-89
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Female	40-49
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Aneurin Bevan	Gynaecological	Female	60-69
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cardiff & Vale	All sites	Male	Unknown
0	patients starting treatment within 62 days of first being suspected of cancer (no suspensions)	November 2020	Cwm Taf Morgannwg	Upper Gastrointestinal	Female	70-79

Showing 1 to 100 of 370,411 rows

Page 1 of 3705

Main information

• Most recent update: 26 September 2025
• Next update expected: 23 October 2025
• Designation: Accredited official statistics
• Data provider: Digital Health and Care Wales (DHCW)
• Data source: Suspected Cancer Pathway (SCP)

Data notes

Overview

• Summary of dataset and variables:

  Under the suspected cancer pathway, a pathway starts at the point of suspicion (for example when a GP makes a referral) and this is when the recorded waiting time starts. A pathway is closed, and their waiting time ends, when the patient starts their first definitive treatment, is downgraded (told they do not have cancer), chooses not to have treatment or if the patient dies. This data measures activity through the number of pathways opened following a suspicion of cancer. Note that a patient may be on more than one pathway.

• Data collection or calculation:

  Open pathway data collected through the NDR method is broadly similar to the previous aggregate data collection, however direct comparisons should not be made between the two sources because the previous method is known to contain many duplicate pathways. This means that the number of pathways opened in months prior to December 2021 should not be directly compared to data from December 2021 onwards.

  Please find this information in the related statistical release, as per the given weblink.

• Statistical quality:

  Suspected cancer pathway data is measured by patient pathways rather than unique patients. This is because a single patient can have multiple cancer pathways opened if cancer is suspected in more than one tumour site. When quality assuring open pathway data for October, November and December 2021, it was estimated that the number of pathways opened is approximately 2-3% higher than the number of unique patients who were suspected of having cancer. Open pathway data collected through the NDR method is broadly similar to the previous aggregate data collection, however direct comparisons should not be made between the two sources because the previous method is known to contain many duplicate pathways. This means that the number of pathways opened in months prior to December 2021 should not be directly compared to data from December 2021 onwards.

• Related reports:
  • Suspected cancer pathway: quality report
  • NHS activity and performance summary, statistical release
  • NHS activity and performance summary: quality report

Published by

• Organisation: Welsh Government
• Contact email: stats.healthinfo@gov.wales

Metadata

The metadata for this dataset is not included when you download the data. You can download this separately. This contains all the information from the 'About this dataset' tab.